Latest Conference Articles

Jeffrey J. Raizer, MD, provides an overview of a study that analyzed the overall survival and toxicity profile of proton therapy for large-volume re-irradiation for patients with recurrent glioma.

Roeland GW Verhaak, PhD, assistant professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the alteration of the p53 pathway and ancestral progenitors to determine if they were associated with tumor recurrence in glioblastoma.

A plenary session held November 15 at the Society of Neuro-Oncology’s (SNO) 2014 Annual Meeting in Miami Beach focused on immunotherapy’s promise as well as its challenges as a treatment for patients with brain cancer.

According to data from a phase I study, the oncolytic virus Delta-24-RGD can infect, replicate, and kill glioma cells in patients.

Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses the combination of the Novo Tumor Treating Fields (NovoTTF) system and temozolomide for patients with glioblastoma.

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, describes the mechanism of action of rindopepimut for recurrent glioblastoma.

Adjuvant temozolomide and the use of the Novo Tumor Treating Fields (NovoTTF) system led to longer progression-free survival and overall survival in patients with glioblastoma.

The vaccine rindopepimut appears to benefit patients with epidermal growth factor receptor variant III mutation (EGFRvIII) in glioblastoma with regard to progression-free survival (PFS) and overall survival (OS).

Ceritinib (Zykadia) showed clinically significant antitumor activity in patients with ALK-rearranged non-small cell lung cancer (NSCLC), including those with brain metastases.

The vaccine rindopepimut (CDX110) in combination with bevacizumab induced tumor regression in a subset of patients with recurrent glioblastoma.

The addition of lomustine to bevacizumab showed superior efficacy compared with either agent alone in patients with recurrent glioblastom, according to the phase II BELOB study presented by Martin van den Bent, MD.

The combination of radiation therapy and procarbazine, CCNU, and vincristine (PCV) prolonged both overall survival (OS) and progression-free survival (PFS) compared with radiation therapy (RT) alone in a phase III study of patients with grade 2 glioma.

Both HPV-positive and -negative head and neck cancers are “outstanding candidates for immunotherapeutic strategies,” said Andrew G. Sikora, MD, PhD, Baylor College of Medicine, at the 2014 Chemotherapy Foundation Symposium.

Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.

PARP inhibitors represent an important class of emerging therapies for the treatment of patients with ovarian cancer and possibly other malignancies, but many scientific questions about the underlying molecular mechanisms that these agents target must be answered before they can be fully employed in clinical practice.

In May 2014, ASCO issued guidelines recommending the administration of adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor (HR)-positive breast cancer, based on data from the collection of 5 clinical trials.

When Gail J. Roboz, MD, took the stage Wednesday to give her talk on what’s ahead in the treatment of acute myeloid leukemia (AML), she admitted feeling a little jealousy toward her colleagues in the lymphoid diseases.

The landscape in lymphoma management continues to evolve, with new therapies and approaches improving established treatment paradigms.

As the targeted therapy era in chronic lymphocytic leukemia (CLL) continues to unfold, two next-generation agents are generating responses with improved safety profiles as single agents and in combination regimens.

The combination of a FLT3L-primed in situ vaccine, low-dose radiotherapy, and a TLR 3 agonist has been shown to be feasible, safe, and immunologically and clinically effective in a phase I/II study for patients with low-grade lymphoma.

Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses vaccine strategies in follicular lymphoma.

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.

Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses results and key takeaways from the final overall survival (OS) analysis of the CLEOPATRA study.

Patients with unresectable melanoma had a significant improvement in the odds of survival when treated in first line with a combination of BRAF and MEK inhibitors, as opposed to anti-BRAF monotherapy.

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses the results of a trial that examined AR-V7 and resistance to enzalutamide and abiraterone in patients with prostate cancer.

Elizabeth Plimack, MD, MS, director, Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a phase Ib study of pembrolizumab for the treatment of patients with bladder cancer.

All patients with metastatic colorectal cancer should undergo RAS mutation testing to ensure optimal patient selection for EGFR inhibitor therapy.

Patients with advanced lung cancer had improved appetite, less weight loss, and a significant increase in lean body mass when treated with a ghrelin agonist, two randomized trials showed.

Afatinib delayed disease progression for approximately one month longer than chemotherapy and helped prevent painful symptoms from worsening for patients with relapsed or metastatic head and neck squamous cell carcinoma.

Almost 60% of patients with advanced non–small cell lung cancer had tumor shrinkage when treated with the PD-L1 inhibitor pembrolizumab.